TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00491062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Study: NCT04225026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419 (avasopasem manganese)
Description: 90 mg, by 60-minute IV infusion, prior to each fraction of RT
Study: NCT00843661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: 10 mg ezetimibe/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: 200 mg fenofibrate/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: 40 mg pravastatin/day
Study: NCT04418102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitic acid rich interesterified fat
Description: Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Stearic acid rich interesterified fat
Description: Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period.
Study: NCT01467817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Control
Description: The control group intervention will test benefits of exercise alone while controlling for investigator contact.
Study: NCT05036512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT021601
Description: Administered orally with water as a single dose in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GBT021601
Description: Administered orally with water as a single dose in the morning.
Study: NCT03563170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine
Study: NCT02493738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sporanox 100mg
Description: Sporanox 100mg single dose under fed condition
Study: NCT04329312

Intervention type: RADIATION
Intervention: Thoracic computed tomography
Description: Patients undergo contrast-enhanced thoracic computed tomography as part of their routine clinical work up.

Intervention type: RADIATION
Intervention: Thoracic computed tomography
Description: Patients undergo contrast-enhanced thoracic computed tomography as part of their routine clinical work up.

Intervention type: RADIATION
Intervention: Thoracic computed tomography
Description: Patients undergo contrast-enhanced thoracic computed tomography as part of their routine clinical work up.
Study: NCT01108718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tempur-Pedic Mattress (2 months)
Description: Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Mattress (2 months)
Description: Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
Study: NCT04269473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telehealth Gait Retraining
Description: Telehealth gait retraining is a novel approach to train participants to adopt a non-rearfoot foot strike pattern during running via telecommunications. During telehealth gait retraining, video of a participant's running form are sent to clinicians over a mobile device app and running form feedback is given. This process is repeated once a week for four weeks and then every other week until week 8.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy Treatment
Description: Participants receiving standard Physical Therapy will visit the Physical Therapy Clinic every 2 to 3 weeks to be treated by a Physical Therapist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy Treatment
Description: Participants receiving standard Physical Therapy will visit the Physical Therapy Clinic every 2 to 3 weeks to be treated by a Physical Therapist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Return to Running Protocol
Description: The Return to Running protocol is a six-phase running volume progression to re-introduce running slowly and safely after experiencing a running-related injury.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Return to Running Protocol
Description: The Return to Running protocol is a six-phase running volume progression to re-introduce running slowly and safely after experiencing a running-related injury.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: At Home Exercise Program
Description: The At Home Exercise Program consists of 4 lower leg and foot exercises that participants can perform on their own time.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: At Home Exercise Program
Description: The At Home Exercise Program consists of 4 lower leg and foot exercises that participants can perform on their own time.
Study: NCT04072887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPD maintenance background therapy
Description: Combination of fluticasone furoate, vilanterol and umeclidinium bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPD maintenance background therapy
Description: Combination of fluticasone furoate, vilanterol and umeclidinium bromide
Study: NCT01605110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Description: Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Air sham
Description: Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
Study: NCT03015935

Intervention type: PROCEDURE
Intervention: visual-assisted entry
Description: First trocar entry will be performed with visual-assisted trocar

Intervention type: PROCEDURE
Intervention: Veress entry
Description: First trocar entry will be performed with Veress
Study: NCT01600989

Intervention type: OTHER
Intervention: blood sampling
Description: Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis

Intervention type: OTHER
Intervention: blood sampling
Description: Blood samples will be taken twice at a 7 day interval
Study: NCT02861248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional micro-plasma radiofrequency treatment
Description: After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
Study: NCT04008251

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Second generation humanized CAR-T cells
Description: Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
Study: NCT01394913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reumatocept (etanercept)
Description: 50mg each week for 30 weeks
Study: NCT03563170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: ERBITUX® injection, for IV infusion)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]
Study: NCT03153566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tuberculin
Description: inject the mother wart with .3 ml tuberculin vaccine every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tuberculin
Description: inject the mother wart with .3 ml tuberculin vaccine every 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: 10 sec 1 cycle into all genital warts

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: 10 sec 1 cycle into all genital warts
Study: NCT02745509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive Intraoperative Peritoneal Lavage
Description: Extensive Intraoperative Peritoneal Lavage
Study: NCT01919489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide + OADs
Description: Liraglutide subcutaneously daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine + OADs
Description: Glargine once daily subcutaneously
Study: NCT01322386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
Study: NCT00277862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated IFN- alpha 2b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated IFN- alpha 2b
Study: NCT02162927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Nitrate
Description: This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Chloride (placebo)
Description: This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
Study: NCT03448302

Intervention type: RADIATION
Intervention: Computed tomography perfusion
Description: Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time \& permeability surface measurements will be obtained.
Study: NCT00277862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated IFN- alpha 2b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated IFN- alpha 2b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study: NCT01394913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel (etanercept)
Description: 50mg each week for 30 weeks
Study: NCT02210975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LES-Stimulation Device
Study: NCT02028650

Intervention type: BIOLOGICAL
Intervention: the first donor's stem cell
Description: HLA-matched stem cell infusion

Intervention type: BIOLOGICAL
Intervention: the second donor's stem cell
Description: HLA-mismatched, the second donor's stem cell infusion
Study: NCT01863082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: practice of physical exercise
Study: NCT00847977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: use of a non balced fluid and of a macromolecular fluid
Description: Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: use of balanced crystalloids fluid and macromolecular fluid
Description: Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
Study: NCT04211194

Intervention type: PROCEDURE
Intervention: Upper GI Endoscopy
Description: Patients with upper gastrointestinal bleeding undergoing endoscopic therapy. Information regarding the need for interventional radiology procedures or surgical interventions will also be collected in patients in whom endoscopic therapy is not successful.
Study: NCT03840993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: over 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: over 16 weeks
Study: NCT01411683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant-retained mandibular overdenture
Description: Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdenture
Description: Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdenture
Description: Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
Study: NCT00551954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose
Description: 100 mg (tablets) t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet t.i.d.
Study: NCT03656822

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine CT
Description: CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine imaging CT with a 3D printed model
Description: CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine imaging MRI with a 3D printed model
Description: will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine MRI
Description: will measure post-operative lesion volume as visualized on the post-operative MRI
Study: NCT02776943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Study: NCT00299130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folate
Description: A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate
Description: A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate
Description: A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to rituximab intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous infusion
Study: NCT03427515

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (ATCC 53103)
Description: 30 days of supplementation, 6x10\^9 CFU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (CNCM I-1079)
Description: 30 days of supplementation, 5x10\^9 CFU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 days of supplementation
Study: NCT01823367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP)
Description: Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
Study: NCT00277862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study: NCT03656822

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine imaging CT with a VR model
Description: CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine imaging MRI with a VR model
Description: will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
Study: NCT01779492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GL2907
Description: once a day
Study: NCT02076646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2 - Ph I
Description: During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2 at RD - Ph II
Description: L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Description: Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Description: Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
Study: NCT00912457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 1 p/day for 28 days
Study: NCT03876899

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Evening Primrose Oil
Description: botanical oil derivative from the seeds of Evening Primrose (Oenothera biennis),1,300 milligrams t.i.d.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill
Study: NCT02091843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DBS of the Basolateral Nucleus of the Amygdala

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DBS of the Basolateral Nucleus of the Amygdala

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala
Study: NCT03108417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous negative external pressure
Description: continuous negative external pressure will be applied to the anterior neck at night
Study: NCT02848391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental
Description: hypobaric flight simulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental
Description: hypobaric flight simulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental
Description: hypobaric flight simulation
Study: NCT04478604

Intervention type: OTHER
Intervention: applied forms to pregnant women
Study: NCT02397044

Intervention type: PROCEDURE
Intervention: Implant surgery
Description: Compare surgical protocols

Intervention type: PROCEDURE
Intervention: Implant surgery
Description: Compare surgical protocols
Study: NCT02696759

Intervention type: OTHER
Group type: OTHER
Intervention: Blood & Fecal Collection
Description: Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
Study: NCT04166097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Smart Interventional Program
Description: 6-week program consisting of weekly didactic sessions that follow the steps outlined in the book.
Study: NCT00571805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varencline
Description: 2.0 mg/day varencline (1.0 mg BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo